United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The market is pricing Pfizer like a perpetual no-growth stock. There are many reasons for this pessimism, some real, some head fakes, which we will examine in this article. Overall, Pfizer at these price levels very likely represents a positive risk/reward for a short to mid-term trade.

Pfizer: Victim Of Vaccine Side Effects

Pfizer is cutting 500 jobs at its Sandwich, Kent site in the U.K. as part of a cost-cutting effort, Sky News reported on Tuesday, citing a company spokesperson.

Pfizer to cut 500 jobs at Kent site - Sky News

Novo Nordisk

Pfizer is looking to buy and develop new revenue drivers. Novo Nordisk aims to penetrate a profitable market even more.

Better Growth Stock: Pfizer vs. Novo Nordisk

Best Buy

Ford Motor Company

Walgreens

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the right catalysts.

4 high yields near 52-week lows worth looking at

Merck

The stock market is rallying after a decline in Treasury yields boosted the case for company shares.

Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.

Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.

Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak

Swiss biotech Basilea Pharmaceutica (OTC:BPMUF) and Pfizer (NYSE:PFE) subsidiary Amplyx Pharmaceuticals have inked a deal worth $37 million, granting Basilea rights to Fosmanogepix, a Phase 3 ready broad-spectrum antifungal. The agreement, announced on Monday, marks a strategic move in the pharmaceutical landscape.

Pfizer stock dips as Swiss Biotech Basilea secures rights to Fosmanogepix

Analysts said upcoming data on Pfizer's obesity pill, danuglipron, will be crucial to how competitive the company can be against Eli Lilly and Novo Nordisk.

Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success

A list of high-quality dividend growth stocks is identified based on proximity to 52-week lows. Pfizer, Bristol-Myers Squibb, ResMed, and NextEra Energy appear attractively valued based on Future and Historical fair valuations. Pfizer appears to be a good investment opportunity due to its high quality, future growth projections, and sustainable dividend.

High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal

Enphase Energy

Prudential Financial

Prudential Financial stands to benefit from higher interest rates, as long as those rates have truly stopped rising. Pfizer's pipeline gives it a great potential for future revenue growth, even as COVID-related treatments wane.

3 Stocks That Can Benefit from a Santa Claus Rally

Disney

Lockheed Martin

QUALCOMM

Toyota Motor

Exxon Mobil

When discussing the next trillion-dollar companies, this article will either be prescient or a total clown show. And while there's good evidence to suggest that I could sadly fall into the latter category, I'm not a complete buffoon.

7 Undervalued Stocks With Potential to Hit Trillion-Dollar Milestone

Pfizer Inc. (NYSE:PFE ) Truist Securities BioPharma Symposium November 9, 2023 12:35 PM ET Company Participants Aamir Malik - Executive Vice President and Chief Business Innovation Officer Conference Call Participants Robyn Karnauskas - Truist Securities Robyn Karnauskas Good afternoon. Thanks so much for joining us.

Pfizer Inc. (PFE) Presents at Truist Securities BioPharma Symposium (Transcript)

Amgen

Gilead Sciences

Sanofi

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024.

5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now

Archer-Daniels-Midland Company

CVS Health

Dow Inc

Energy Transfer LP Unit

ManpowerGroup

MetLife

Omnicom Group

Philip Morris

Southern Company

Verizon

The Summer, 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. Dogcatcher's quest to sniff-out the best dividend buys focused on 68 industry leaders using YCharts 11/8/23. Those 68 industry leaders were segmented into 21 business sectors ranging (alphabetically) from apparel to wholesalers. Three of the 68 are not listed on U.S. exchanges. Their data was excluded. 58 dividend yielding stocks led those 68 industry leaders and ranged 0.19% to 9.56% in annual-yield and ranged -1.29% to 54.34% in broker-estimated one-year price-target-upsides by YCharts 11/8/23 reckoning.

5 Fair-Priced November Fortune 500 Industry-Leader Dogs Out Of 68

Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.

WHO's new COVID guidelines see fewer patients requiring hospitalization

BlackBerry

General Motors

Oracle

Rite Aid

Charles Schwab

Texas Instruments

Many once great stocks have lost their shine. Blue-chip companies that for years were reliable winners in the market have fallen on hard times and their share prices have steadily eroded.

7 Blue-Chip Stocks to Sell and Never Buy Back

Enbridge

Kraft Heinz

Kraft Heinz owns popular brands that have enabled it to raise prices and keep sales growing. Enbridge's yield of 7.6% could be an appealing income stream for dividend investors.

Got $5,000? Get the Most Bang for Your Buck With These 4%-Plus Dividend Yield Stocks

Abbott Labs

Accenture Plc

FedEx

General Dynamics

Honeywell

Microsoft

AT&T

Northrop Grumman

Raytheon

Quiver Quantitative, the pioneering company behind an alternative data platform designed for retail investors, has been actively tracking stock market trades made by US Congress members and other political figures. Some of the trades have been notably controversial, mainly due to their timing or because they violated federal laws.

15 stocks with the closest US government connections

News for Pfizer Stock (PFE)